|
1
|
Klaassen CD: Heavy metals and heavy-metal
antagonists. The Pharmacological Basis of Therapeutics. Gilman:
McGraw-Hill; New York, NY: pp. 649–1672. 1996
|
|
2
|
Cyranoski D: Arsenic patent keeps drug for
rare cancer out of reach of many. Nat Med. 13:10052007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun HD, Ma L, Hu XC and Zhang TD: Ai-Lin I
treated 32 cases of acute promyelocytic leukemia. Chin J Integr
Chin W Med. 12:170–171. 1992.
|
|
4
|
Zhang TC, Cao EH, Li JF, Ma W and Qin JF:
Induction of apoptosis and inhibition of human gastric cancer
MGC-803 cell growth by arsenic trioxide. Eur J Cancer.
35:1258–1263. 1999. View Article : Google Scholar
|
|
5
|
Shen ZY, Shen J, Cai WJ, Hong C and Zheng
MH: The alteration of mitochondria is an early event of arsenic
trioxide induced apoptosis in esophageal carcinoma cells. Int J Mol
Med. 5:155–158. 2000.PubMed/NCBI
|
|
6
|
Akao Y, Nakagawa Y and Akiyama K: Arsenic
trioxide induces apoptosis in neuroblastoma cell lines through the
activation of caspase 3 in vitro. FEBS Lett. 455:59–62. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uslu R, Sanli UA, Sezgin C, Karabulut B,
Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated
cytotoxicity and apoptosis in prostate and ovarian carcinoma cell
lines. Clin Cancer Res. 6:4957–4964. 2000.
|
|
8
|
Chow SK, Chan JY and Fung KP: Inhibition
of cell proliferation and the action mechanisms of arsenic trioxide
(As2O3) on human breast cancer cells. J Cell Biochem. 93:173–187.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ye J, Li A, Liu Q, Wang X and Zhou J:
Inhibition of mitogen-activated protein kinase kinase enhances
apoptosis induced by arsenic trioxide in human breast cancer MCF-7
cells. Clin Exp Pharmacol Physiol. 32:1042–1048. 2005. View Article : Google Scholar
|
|
10
|
Crociani O, Guasti L, Balzi M, et al: Cell
cycle-dependent expression of HERG1 and HERG1B isoforms in tumor
cells. J Biol Chem. 278:2947–2955. 2003. View Article : Google Scholar
|
|
11
|
Guasti L, Crociani O, Redaelli E, Pillozzi
S, Polvani S, Masselli M, Mello T, Galli A, Amedei A, Wymore RS, et
al: Identification of a posttranslational mechanism for the
regulation of hERG1 K+ channel expression and hERG1 current density
in tumor cells. Mol Cell Biol. 28:5043–5060. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arcangeli A: Expression and role of hERG
channels in cancer cells. Novartis Found Symp. 266:225–232.
2005.PubMed/NCBI
|
|
13
|
Wang Y, Zhang Y, Yang L, Cai B, Li J, Zhou
Y, Yin L, Yang L, Yang BF and Lu YJ: Arsenic trioxide induces the
apoptosis of human breast cancer MCF-7 cells through activation of
caspase-3 and inhibition of HERG channels. Exp Ther Med. 2:481–486.
2011.PubMed/NCBI
|
|
14
|
Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng
L, Zhou H and Zhao RC: miR-145 inhibits breast cancer cell growth
through RTKN. Int J Oncol. 34:1461–1466. 2009.PubMed/NCBI
|
|
15
|
Kato M, Paranjape T, Müller RU, Nallur S,
Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB and Slack FJ:
The mir-34 microRNA is required for the DNA damage response in vivo
in C. elegans and in vitro in human breast cancer cells. Oncogene.
28:2419–2424. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Valastyan S, Reinhardt F, Benaich N,
Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and
Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits
breast cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu G, Qiu XL, Zhou L, Zhu J, Chamberlin R,
Lau J, Chen PL and Lee WH: Small molecule targeting the Hec1/Nek2
mitotic pathway suppresses tumor cell growth in culture and in
animal. Cancer Res. 68:8393–8399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B,
Zhang Y, Xu C, Bai Y, Wang H, et al: The muscle-specific microRNA
miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1
and KCNJ2. Nat Med. 13:486–491. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang
F, Zhang Y, Shan H, Luo X, Bai Y, et al: MicroRNA-328 contributes
to adverse electrical remodeling in atrial fibrillation.
Circulation. 122:2378–2387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shan H, Zhang Y, Lu Y, Zhang Y, Pan Z, Cai
B, Wang N, Li X, Feng T, Hong Y, et al: Downregulation of miR-133
and miR-590 contributes to nicotine-induced atrial remodelling in
canines. Cardiovasc Res. 83:465–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cai B, Pan Z and Lu Y: The roles of
microRNAs in heart diseases: A novel important regulator. Curr Med
Chem. 17:407–411. 2010. View Article : Google Scholar
|
|
23
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. Feb 4–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vahdat LT, Pruitt B, Fabian CJ, Rivera RR,
Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, et
al: Phase II study of eribulin mesylate, a halichondrin B analog,
in patients with metastatic breast cancer previously treated with
an anthracycline and a taxane. J Clin Oncol. 27:2954–2961. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li H, Liu L, Guo L, et al: HERG K+ channel
expression in CD34+/CD38−/CD123(high) cells and primary leukemia
cells and analysis of its regulation in leukemia cells. Int J
Hematol. 87:387–392. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Afrasiabi E, Hietamäki M, Viitanen T,
Sukumaran P, Bergelin N and Törnquist K: Expression and
significance of HERG (KCNH2) potassium channels in the regulation
of MDA-MB-435S melanoma cell proliferation and migration. Cell
Signal. 22:57–64. 2010. View Article : Google Scholar
|
|
27
|
Zhao J, Wei XL, Jia YS and Zheng JQ:
Silencing of herg gene by shRNA inhibits SH-SY5Y cell growth in
vitro and in vivo. Eur J Pharmacol. 579:50–57. 2008. View Article : Google Scholar
|
|
28
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng
L, Zhou H and Zhao RC: miR-145 inhibits breast cancer cell growth
through RTKN. Int J Oncol. 34:1461–1466. 2009.PubMed/NCBI
|
|
30
|
Kong W, He L, Coppola M, Guo J, Esposito
NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival,
growth, and chemosensitivity by targeting FOXO3a in breast cancer.
J Biol Chem. 285:17869–17879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song B, Wang C, Liu J, Wang X, Lv L, Wei
L, Xie L, Zheng Y and Song X: MicroRNA-21 regulates breast cancer
invasion partly by targeting tissue inhibitor of metalloproteinase
3 expression. J Exp Clin Cancer Res. 29:292010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee EJ, Baek M, Gusev Y, Brackett DJ,
Nuovo GJ and Schmittgen TD: Systematic evaluation of microRNA
processing patterns in tissues, cell lines, and tumors. RNA.
14:35–42. 2008. View Article : Google Scholar :
|
|
33
|
Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W
and Yang Z: MiR-328 expression is decreased in high-grade gliomas
and is associated with worse survival in primary glioblastoma. PLoS
One. 7:e472702012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shah MY, Pan X, Fix LN, Farwell MA and
Zhang B: 5-Fluorouracil drug alters the microRNA expression
profiles in MCF-7 breast cancer cells. J Cell Physiol.
226:1868–1878. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Eiring AM, Harb JG, Neviani P, Garton C,
Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, et al:
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation
of mRNA translation in leukemic blasts. Cell. 140:652–665. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pan YZ, Morris ME and Yu AM: MicroRNA-328
negatively regulates the expression of breast cancer resistance
protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol.
75:1374–1379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Paduano F, Dattilo V, Narciso D, Bilotta
A, Gaudio E, Menniti M, Agosti V, Palmieri C, Perrotti N, Fusco A,
et al: Protein tyrosine phosphatase PTPRJ is negatively regulated
by microRNA-328. FEBS J. 280:401–412. 2013. View Article : Google Scholar
|
